Chronic hepatitis B
Conditions
Interventions
Control group:Entecaciv Dispersible Tablets
Test group:Spleen Aminopeptide Oral Solution + Entecaciv Dispersible Tablets
Sponsors
The First Affiliated Hospital of China Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-70 years old, male or female; 2. Clinical diagnosis of chronic hepatitis B virus infection HBsAg positive for more than six months, HBeAg positive; 3. Volunteer and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with decompensated cirrhosis (Child grades B and C); 2. Patients with liver cancer; 3. Patients who have received relevant antiviral or reduced-enzyme therapy in the last 3 months; 4. Patients who had used interferon in the past 6 months; 5. Patients simultaneously taking hormones or immune agents or chemotherapy drugs; 6. Female patients during pregnancy or pregnancy; 7. Patients who are unable to comply with the study protocol, or who have other conditions that the investigator deems unsuitable for inclusion; 8. Patients allergic to the investigational drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effect on T cell subsets in peripheral blood of patients receiving experimental group; | — |
Secondary
| Measure | Time frame |
|---|---|
| HBV DNA Roche test showed that HBV DNA complete response rate was IU/ML;Rate and level of HBV RNA decline between the two groups;Glutamic oxalacetic transaminase and glutamic pyruvic transaminase decreased levels between the two groups;Differences in quantitative changes of hepatitis B surface antigen before and after treatment between the two groups;The difference of liver hardness between the two groups before and after treatment;Differences in cytokine changes before and after treatment between the two groups; | — |
Countries
China
Contacts
Public ContactDeng Baocheng
The First Affiliated Hospital of China Medical University
Outcome results
None listed